Insider buying last 90 days
No open-market insider purchases were filed for ARGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ARGX insider filing, plotted on the chart in Gekko.Open ARGX in Gekko
argenx (ARGX) Stock Analysis & Forecast
$990.32−5.45 (−0.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Gekko Brief
AI summaryARGX closes at $990.32, down 0.5%, holding above both its 50-day average of $939.03 and its 200-day average of $848.11, consistent with an intact uptrend. The GekkoIndex reads 55.8, placing the stock in the Neutral zone. Price sits 4.3% below Gekko Fair Value of $1,034.34.
Recent attention has centered on corporate governance and comparative positioning rather than product or trial news. argenx announced the results of its Extraordinary General Meeting of Shareholders, appointing Thomas M. Brakel and Khurem Farooq as non-executive directors to its Board. Separately, coverage has framed argenx against Bristol Myers Squibb (BMY) on relative value grounds, and the company presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A filing showed Tidal Investments LLC increasing its position in the second quarter, though this sits alongside the governance and conference news rather than driving the week on its own.
No confirmed earnings date currently appears on the calendar, with the last report on 23 July 2026 showing EPS of $7.32 against an estimate of $6.13, a reaction of 7.8%, and beats in 7 of the last 8 quarters. Seasonality over the next 20 trading days has averaged a 0.8% gain across 5 years, rising in 2 of those years. Analyst coverage stands at 20 buy and 1 hold ratings among 21 firms, with a consensus target of $1,179.74, implying 19.1% upside from current levels. No insider, Congress, or unusual options activity appears in the current windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 21, 2026 from the data above.
Price vs fair value
Close $990.32200-day averageGekko Fair Value $1,034.34
Key stats
- Market cap
- $61.59B
- P/E ratio
- 37.6
- Forward P/E
- 26.6
- EPS, TTM
- $26.21
- Revenue, TTM
- $5.32B
- Profit margin
- 32.3%
- Dividend yield
- —
- Beta
- -0.02
- Volume
- 243,308 avg 236,268
- 1-year return
- +34.9%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.5%
- 50-day average
- $939.03
- 200-day average
- $848.11
- Next earnings
- —
- Shares outstanding
- 62.19M
argenx swing-trade checklist
argenx scores 1 supportive, 3 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $990.32 is above the 50-day ($939.03) and 200-day ($848.11) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.8, Neutral
Reading 55.8 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.3% below
Price is within 5% of Gekko Fair Value (4.3% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalitymixed
+0.8% on average
From this point in the calendar, the next 20 trading days averaged +0.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
argenx stock chart and price history
argenx closed at $990.32 on Sep 18, 2026, +34.9% over the past year, inside a 52-week range of $661.85 to $1,072.75.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.1%
- 3 months
- +12.8%
- 6 months
- +44.7%
- 1 year
- +34.9%
The full ARGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ARGX in Gekko
Follow argenx through every session
Put ARGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ARGX in GekkoFree for 7 days. No credit card required.
About argenx
argenx works on medicines for people whose immune systems attack their own bodies, turning early research into treatments that reach patients. Its main therapy, efgartigimod, underpins the medicines it sells under the VYVGART, VYVGART HYTRULO and VYVDURA brands, currently used against nerve and blood disorders where the immune system is overactive, with additional uses under study in a long list of other conditions.
Alongside these approved products, the company keeps a wider set of experimental drugs moving through testing, among them empasiprubart, ARGX-119, ARGX-213 and other early-stage candidates aimed at different immune targets. Much of this work relies on outside partners: argenx has struck deals with companies such as AbbVie, Zai Lab and LEO Pharma, joined forces with Genmab on antibody research, and linked up with IQVIA for drug-safety support, plus various academic and research collaborators. Sales and trials reach patients across the Americas, Asia, Europe, the Middle East and Africa.
Founded in Amsterdam in 2008, argenx operates under the European public-company structure known as an SE. Its stock trades under the ticker ARGX.
- Sector
- Health technology
- Website
- argenx.com
argenx GekkoIndex: the smart money zone
argenx’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.8, in the Neutral zone, down 1.3 points over five sessions.
55.8Neutral
Down 1.3 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | +0.5% | +2.9% | ||
| Accumulation | 122 | +0.6% | +3.6% | ||
| Neutral (current zone) | 392 | +1.3% | +3.9% | ||
| Distribution | 58 | −0.8% | +2.3% | ||
| Selling | 2 | Too few readings yet | |||
Average ARGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ARGX price, zone by zone.Track ARGX in Gekko
Is argenx stock overvalued? Gekko Fair Value
argenx trades 4.3% below Gekko Fair Value of $1,034.34, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what argenx shares are worth, recalculated every trading day.
$1,034.34
Gekko Fair Value, Sep 18, 2026
4.3% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open ARGX in Gekko
argenx insider and Congress trading
No open-market insider purchases were filed for argenx, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ARGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ARGX, plotted on the chart in Gekko.Open ARGX in Gekko
Buybacks
argenx has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2024
- $20.08M
- As a share of market cap
- 0.03%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold ARGX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
argenx earnings: next date and track record
argenx beat the EPS estimate in 7 of its last 8 reports, moving 6.7% on average across the report.
7 of 8reports beat the EPS estimate
±6.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $7.32 est $6.13 | $2.82B est $1.63B | +7.8% |
| May 7, 2026 | $5.52 est $4.92 | $2.41B est $1.45B | −3.1% |
| Feb 26, 2026 | $6.79 est $5.95 | — | −6.1% |
| Oct 30, 2025 | $5.18 est $4.37 | $948.0M est $1.28B | −0.4% |
| Jul 31, 2025 | $3.26 est $2.61 | — | +12.5% |
| May 8, 2025 | $2.27 est $2.05 | $1.35B est $861.8M | −11.8% |
| Mar 31, 2025 | $0.71 est $1.70 | $790.7M | −3.7% |
| Oct 31, 2024 | $1.39 est $0.10 | $901.9M est $665.1M | +8.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
argenx stock forecast and analyst price targets
Analysts’ average 12-month price target for argenx is $1,179.74, +19.1% from the last close, from 21 firms rating the stock in the last 90 days.
$1,179.74consensus 12-month target, +19.1% from the last close
Now $990.32Avg $1,179.74
Low $932High $1,415
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Bank of America Securities | $1,136 | +14.7% |
| Sep 15 | Jefferies | $1,215 | +22.7% |
| Sep 3 | Wedbush | $1,150 | +16.1% |
| Sep 3 | Jefferies | $1,215 | +22.7% |
| Sep 2 | William Blair | — | — |
+3.9%average 20-day move after past Neutral readings
+0.8%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
argenx seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, argenx averaged +0.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 1 of 5 |
| Next 10 trading days | −1.2% | 2 of 5 |
| Next 15 trading days | −1.9% | 1 of 5 |
| Next 20 trading days | +0.8% | 2 of 5 |
| Next 30 trading days | +2.0% | 3 of 5 |
For scale, ARGX’s typical 20-trading-day move in either direction is about 5.5%.
argenx market cap and key statistics
argenx’s market cap is $61.59B, with a P/E ratio of 37.6 and revenue of $5.32B over the last twelve months.
Valuation
- Market cap
- $61.59B
- P/E ratio
- 37.6
- Forward P/E
- 26.6
- EPS, TTM
- $26.21
- Gekko Fair Value
- $1,034.34
Trading
- Volume
- 243,308
- Avg volume, 20 days
- 236,268
- 52-week high
- $1,072.75
- 52-week low
- $661.85
- Shares outstanding
- 62.19M
Financials
- Revenue, TTM
- $5.32B
- Profit margin
- 32.3%
- Return on equity
- 23.6%
- Quarterly earnings growth, YoY
- +95.2%
Risk and income
- Beta
- -0.02
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.5%
argenx stock news this week
5 headlines about argenx from the past week, newest first, each linking to the publisher.
- BMY vs. ARGX: Which Stock Is the Better Value Option?Zacks Investment Research, Sep 18
- Argenx SE Announces Board Appointmentsmarketscreener.com, Sep 17
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsGlobeNewsWire, Sep 17
- Tidal Investments LLC Grows Holdings in argenex SE $ARGXDefense World, Sep 17
- argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 14
argenx stock FAQ
What is argenx’s market cap?
argenx’s market cap is $61.59B at the Sep 18, 2026 close of $990.32, with 62.19M shares outstanding. The shares trade on a P/E ratio of 37.6.
What is the argenx stock forecast?
The consensus analyst 12-month price target for argenx is $1,179.74, +19.1% from the last close. Of the 21 firms that rated the stock in the last 90 days, 20 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is argenx stock overvalued or undervalued?
On Gekko’s estimate argenx is about fair value: the Sep 18, 2026 close of $990.32 is 4.3% below Gekko Fair Value of $1,034.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is argenx’s 52-week high and low?
argenx’s 52-week high is $1,072.75 and its 52-week low is $661.85; it closed at $990.32 on Sep 18, 2026, +34.9% over the past year.
Is argenx stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 4 items with data read as supportive (trend), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See argenx the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.